Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Carfilzomib--dexamethasone vs bortezomib--dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Autor: Chng, W.-J. Goldschmidt, H. Dimopoulos, M.A. Moreau, P. Joshua, D. Palumbo, A. Facon, T. Ludwig, H. Pour, L. Niesvizky, R. Oriol, A. Rosiñol, L. Suvorov, A. Gaidano, G. Pika, T. Weisel, K. Goranova-Marinova, V. Gillenwater, H.H. Mohamed, N. Feng, S. Aggarwal, S. Hájek, R.

The randomized phase 3 study ENDEAVOR demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in relapsed or refract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4b0aed5492b1c55c20b320e77296dc71
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2954000

Abstracts of the 37th American Cytogenetics Conference

Autor: S.M. White, R. Mollicone, M. Rozek, Z. Tümer, T. Opiola, J.-J. Candelier, C.R. Bonvicino, H. Winking, A. Hebinck, H. Kuiper, Ch. Zühlke, H. Yasue, J.M. Perez de la Lastra, S. Kiuchi, A. Pienkowska, N. Arnal, B. Gläser, C. Ngo, H. Mehenni, C. Steinlein, P.S. D’Andrea, R.P.M.A. Crooijmans, A. Eggen, C. Zijlstra, M. Yerle, U. Butzmann, S.E. Antonarakis, Y.E. Shahein, E. Anton, R. Korstanje, D.F. de Andres-Cara, N.A. de Haan, R. Heilig, B. Brenig, J. Egozcue, C. Delcros, M. Østergaard, G.F. Gillissen, A. Wandall, R. Kreutz, R.J. McKinlay Gardner, F. Piumi, M. Mahony, A. Robic, C. Ozouf-Costaz, N. Tommerup, T. Haaf, C. Rodellar, C. Szpirer, F. Vidal, P.A. Ioannou, P.M. Kroisel, C. Drögemüller, K. Buchet-Poyau, Y. Takagaki, T.L. Harboe, C. Wilhelm, F. Porto-Foresti, J. Barciszewski, A.C.M. Bonné, M.T. Roldan-Arjona, C. Rogel-Gaillard, H. Hiraiwa, Y. Muneta, M. Grzmil, P. Zaragoza, C. Bonillo, H.A. van Lith, J. Kunz, A. Dalski, O. Distl, F. Laccone, D. Milan, C. Windpassinger, T. Awata, H. Uenishi, J. Szpirer, R. Fries, A.A. Bosma, F. Foresti, M.F.Z. Daniel-Silva, H. Hayes, R. Roy, H. Omran, P. Pinton, S. Schlickum, E. Petek, E. Schwinger, L. Li, P. Coullin, C. Knorr, L.F.M. van Zutphen, J. Blanco, H.P. Klinger, A. Volz, J. Mißbach, I.B. Otazu, E. Northrop, C. Andersen, P. Burfeind, M. Den Bieman, M. Meins, R. Melkaoui, J. Beck, U. Radhakrishna, M. Gautier, R. Oriol, L.F. Almeida-Toledo, I. Nanda, K. Wagner, F. Habermann, V. Petrovic, M. Schmid, R. Yamamoto, P. Moore, P. van Vooren, G. Hauke, H. Zürcher, F. Hildebrandt, C.G. Ziegler, J. Koch, P. Laurent, J.L. Williams, M.A.M. Groenen, J.J. Garrido, C. Schelling, S. Yadav, C. Kosan, H.R. Slater

Publikováno v: Cytogenetic and Genome Research. 97:261-275

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25ae8045d27dfe35b1f201845d6a7df6
https://doi.org/10.1159/000066630

SPECIFIC INTRAVENOUS CARBOHYDRATE THERAPY A NEW CONCEPT IN INHIBITING ANTIBODY-MEDIATED REJECTION—EXPERIENCE WITH ABO-INCOMPATIBLE CARDIAC ALLOGRAFTING IN THE BABOON

Autor: D. K.C. COOPER, Y. YE, M. NIEKRASZ, M. KEHOE, M. MARTIN, F. A. NEETHLING, S. KOSANKE, L. E. DEBAULT, G. WORSLEY, N. ZUHDI, R. ORIOL, E. ROMANO

Publikováno v: Transplantation. 56:769-777

Heterotopic allografting of ABO-incompatible donor hearts in recipient baboons "hyperimmunized" against the incompatible A or B antigen (n = 3) was followed by hyperacute antibody-mediated vascular rejection within a mean of 19 min. The A and B epito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a01b631939e5710589f4c04512ff190
https://doi.org/10.1097/00007890-199310000-00001

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.